CD274 and neoplasm: Together, with the different read-outs from available clinical companion diagnostic assays for anti-PD-L1 therapy in mind [27, 28], this encourages the practice of imaging with a radiolabelled version of the therapeutic antibody enabling quantification of exact distribution pattern within the body and the delivery to tumour prior to and during therapy.